ecancermedicalscience

Review

Infracentimetric HER-2 positive breast tumours—review of the literature

18 Nov 2015
Danilo da Fonseca Reis Silva, Joana M Ribeiro

Breast cancer is the most common malignant neoplasm in the world among women. As a result of the dissemination of population screening programmes, about half of non-metastatic breast cancers are now diagnosed at stage I. 10–15% of T1abN0 tumours over-express human epidermal growth factor (HER-2). These tumours have a globally excellent prognosis, however, treatment with chemotherapy and/or targeted therapy may further improve outcomes in selected cases. In this article, we will review studies with information on prognosis and benefit of adjuvant therapy for T1abN0 HER-2 breast cancer.

Related Articles

Anass Baladi, Hassan Abdelilah Tafenzi, Fatim-Zahra Megzar, Ibrahima Kalil Cisse, Othmane Zouiten, Leila Afani, Ismail Essaadi, Mohammed El Fadli, Rhizlane Belbaraka
Nashivai E Kivuyo, Daniel W Kitua, Martin E Chikelea, Mungeni A Misidai, Ally H Mwanga, Obadia V Nyongole, Larry O Akoko
Nithiya Sinarajoo, Yek-Ching Kong, Ranjit Kaur, Ros Suzanna Bustamam, Nur Fadhlina Abdul Satar, Sharminii Jaya-Prakason, Harenthri Devy Alagir Rajah, Mahmoud Danaee, Cheng-Har Yip, Nirmala Bhoo-Pathy